In 150 adults with type 2-low mild asthma (89 per-protocol), LAMA was non-inferior to ICS for composite treatment success (+7.9 points, 95% CI -2.9 to 18.8), but non-inferiority was not shown when uncompleted phases counted as failures. Exacerbations did not differ.
RCTn = 150
Kang et al. Long-Acting Muscarinic Antagonist as an Alternative to Inhaled Corticosteroids in Type 2-Low Mild Asthma: A Randomized Crossover Non-inferiority Trial